Merck, Eisai and Phase 3
Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that form in and around the ...
Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...
In a report released on January 24, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...
Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...
Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...
Merck expands operations to position itself as a critical manufacturing hub in the APAC region: Our Bureau, Bengaluru Monday, January 27, 2025, 10:45 Hrs [IST] Merck has announced ...
Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...
GlobalData on MSN3d
Merck and Opentrons to automate assay kits on custom workstationMerck KGaA (Merck) and Opentrons Labworks have announced a partnership to automate assay kits on a ‘custom’ Opentrons Flex ...
Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of ...
Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback